Cure Research for Adrenoleukodystrophy
Cure Research discussion for Adrenoleukodystrophy:
People with ALD accumulate high levels of saturated, very long chain fatty acids in their brain and adrenal cortex because the fatty acids are not broken down by an enzyme in the normal manner. So, when the ALD gene was discovered in 1993, it was a surprise that the corresponding protein was in fact a member of a family of transporter proteins, not an enzyme. It is still a mystery as to how the transporter affects the function the fatty acid enzyme and, for that matter, how high levels of very long chain fatty acids cause the loss of myelin on nerve fibers.
More recently, all the transporters related to ALD protein have been found in the yeast Saccharomyces cerevisiae, and a mouse model for the human disease has been developed. These and other molecular biology approaches should further our understanding of ALD and hasten our progress toward effective therapies
(Source: Genes and Disease by the National Center for Biotechnology)
Adrenoleukodystrophy Treatment: Book Excerpts
Clinical Trials for Adrenoleukodystrophy
Some of the clinical trials for Adrenoleukodystrophy include:
Hear one woman's story as she participates in a clinical trial to help fight CML.
If one promising drug fails to help against chronic myeloid leukemia, what can be done? Listen to experts explain your options for hard to treat...
Standard treatment for chronic myeloid leukemia can occasionally fail. New studies show an increasing number of alternative treatments may be...
A majority of people with CML do well with treatments. But a few will develop serious side effects or develop drug resistance. Listen to experts...
See full list of 11 related videos
» Next page: Statistics about Adrenoleukodystrophy
Rate This Website
What do you think about the features of this website?
Take our user survey and have your say:
Website User Survey
Medical Tools & Articles:
Next articles:
Tools & Services:
Medical Articles:
Forums & Message Boards
- Ask or answer a question at the Boards: